Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-08-15 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds (募集资金存放与实际使用情况的专项报告). It details the amount of funds raised through a public offering, the use of these funds, the management and supervision of the funds, and confirms that the funds have been used as intended without misuse or changes in purpose. It includes detailed tables of fund usage and references regulatory approvals and audit reports related to the fundraising. The document length is 3537 characters, which is relatively short but contains substantive financial and usage data about the fundraising proceeds. This type of report is a specialized disclosure on capital raising and fund usage, which fits the category of Capital/Financing Update (CAP) rather than a full Annual Report (10-K) or Audit Report (AR). It is not a simple announcement of a report publication (RPA) because it contains detailed data and explanations. Therefore, the best classification is CAP with high confidence.
2024-08-15 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" and contains detailed financial data for the six-month period ending June 30, 2024. It includes comprehensive financial figures such as total assets, net profit, cash flow, earnings per share, and shareholder structure. The document also discusses business operations, R&D, production, and sales models, which are typical contents of an interim or quarterly report. The length of the document (6722 characters) and the presence of substantive financial data and analysis confirm it is a full interim report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
第五届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth board of directors' fourth meeting of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting's attendance, the approval of the 2024 semi-annual report and a special report on the use of raised funds, and voting results. The document does not contain the actual semi-annual report or financial data but references where these reports can be found. The document is primarily about board meeting resolutions and approvals, not the reports themselves. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1250 characters), and it is an announcement of meeting resolutions rather than a full report or financial statement.
2024-08-15 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report". It covers the period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as income, profit, assets, liabilities, and operational details, which are typical of an interim or quarterly report. The document is about 15,000 characters long, which is substantial and contains actual financial statements and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-15 Chinese
第五届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on specific agenda items, including approval of the 2024 semi-annual report and a special report on the use of raised funds. The document references the actual semi-annual report and special report as being published separately on the Beijing Stock Exchange information platform, indicating this document is not the report itself but an announcement of the meeting resolutions. The document length is short (1079 characters), consistent with a meeting resolution announcement rather than a full financial report. Therefore, this fits best under Regulatory Filings (RNS) as a general regulatory announcement of meeting resolutions and approvals, not the full interim report or financial statements themselves.
2024-08-15 Chinese
2023 年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual equity distribution (dividend) plan approved at the shareholders' meeting. It details the dividend amount, tax treatment, record date, and payment date. The document is relatively short (1712 characters) and focuses on dividend distribution specifics rather than presenting financial statements or comprehensive financial performance. It is not a full annual report or earnings release but a formal notice about dividend payment. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2024-05-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.